News

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis (MG). The SPA agreement indicates that the FDA has determined that the proposed trial design is acceptable to support a future Biologics License Application for Descartes-08 in MG, subject to the ultimate outcome of the trial.

COLUMBIA, Md., Jan. 24, 2025 /PRNewswire/ — TEDCO, Maryland’s economic engine for technology companies, announced nine awardees for the inaugural Maryland Student Venture Showcase and Pava LaPere Innovation Awards. The awards, funded by the State of Maryland through the Pava LaPere Legacy of Innovation Act of 2024, recognize and support outstanding student entrepreneurs from colleges and universities in the Baltimore–Towson–Columbia metropolitan statistical area.

“The Maryland Student Venture Showcase and Pava LaPere Innovation Awards are a testament to the incredible talent and innovation coming out of Maryland’s colleges and universities,” said Troy LeMaile-Stovall, TEDCO CEO. “We are excited to support these outstanding student entrepreneurs as they work to grow successful businesses.”

The 43rd Annual J.P. Morgan Healthcare Conference, held from January 13–16, 2025, in San Francisco, once again brought together industry leaders, investors, and innovators from around the globe. As the largest healthcare investment symposium, the event offered a platform to discuss breakthroughs in cancer, pain management, neurodegenerative diseases, artificial intelligence (AI) in drug development, and strategies for mergers and acquisitions (M&A).

Several of BioHealth Innovation’s (BHI) Entrepreneurs-in-Residence (EIRs) attended, sharing insights and observations from this pivotal event.

Emergent BioSolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose treatment portfolio, which includes Narcan. The growing US opioid epidemic (including synthetic fentanyl) and its treatments will provide future growth drivers for Emergent, said Joe Papa, president and CEO of Emergent, at this year’s J.P. Morgan 43rd Annual Healthcare Conference on 15 January.

Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, then turning it around and ultimately transforming the company,” Papa told the conference. “It’s a multiyear process.”

COLUMBIA, Md., (January 24, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Builder Fund investment in Nostopharma, a musculoskeletal therapeutic platform company focused on treating complications of trauma, orthopedic surgery and rare diseases musculoskeletal sequalae. TEDCO’s Builder Fund operates under the umbrella of Social Impact Funds and not only provides companies with investment funds but also offers various resources, including executive support, mentorship and assorted networking opportunities.

ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ascentage Pharma, are expected to be approximately $126.4 million. In addition, Ascentage Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial public offering price, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker “AAPGV” on a “when-issued” basis, and on January 27, 2025, under the ticker symbol “AAPG” for “regular-way” trading. The offering is expected to close on January 28, 2025, subject to customary closing conditions.

COLLEGE PARK, Md.–(BUSINESS WIRE)– The following is a statement from Peter Chapman, Chairman and CEO of IonQ (NYSE: IONQ):

Today’s classical computing hardware is limited by computational capacity and power requirements in ways that will likely prohibit society from ever being able to solve some of its most pressing problems.

IonQ’s current #AQ 36 Forte Enterprise systems are already providing insight to solutions for customers today, and our upcoming #AQ 64 Tempo systems in 2025 and next-generation #AQ 256 systems will enable us to tackle increasingly complex problems to deliver near-term business value. One of the areas facing the most significant potential disruption is strong AI, where we believe natively quantum AI will outperform classical AI.

Rockville, MD, United States, October 22, 2024 — On Demand Pharmaceuticals (ODP), a pioneering leader in agile distributed medicine manufacturing, is thrilled to announce the appointment of Jarrod Borkat, MBA, as Chief Strategy and Commercial Officer, effective October 21, 2024. Jarrod brings more than two decades of experience in strategic leadership and commercialization, including senior roles at AstraZeneca and Boehringer Ingelheim, where he successfully drove innovation and growth in the pharmaceutical industry.

Jarrod joins ODP at a critical juncture as the company prepares to commercialize its groundbreaking platform for on-demand medicine manufacturing. This innovative technology enables healthcare providers to produce patient-ready generic sterile injectables at the point of care, addressing persistent challenges in drug shortages and supply chain vulnerabilities.

BALTIMORE, MD, UNITED STATES, January 21, 2025 /EINPresswire.com/ — Linshom Medical announced today U.S. Food and Drug Administration, 510(k), clearance of the company’s two-piece, wearable respiratory sensor.

This clearance brings Linshom Medical closer to commercial launch of a product that has proven to provide clinicians 12 minutes advance notice of respiratory decline in an NIH funded clinical study at Ohio State University.